Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Alnylam Acquires Rights To VEGF Patents From Hybridon

Aug. 5, 2004

By Aaron Lorenzo

Elusys Raises $10.2M Via Series D Financing Round

Aug. 4, 2004

By Aaron Lorenzo

Elusys Raises $10.2M Via Series D Financing Round

Aug. 4, 2004

By Aaron Lorenzo

Though Not Approved, La Jolla's Riquent Begins Phase IV Study

Aug. 3, 2004

By Aaron Lorenzo

Though Not Approved, La Jolla's Riquent Begins Phase IV Study

Aug. 3, 2004

By Aaron Lorenzo

CV Therapeutics Gets Second Ranexa SPA For Angina, ACS

Aug. 2, 2004

By Aaron Lorenzo

CV Therapeutics Gets Second Ranexa SPA For Angina, ACS

Aug. 2, 2004

By Aaron Lorenzo

SGX Acquires First Clinical Drug: Troxatyl For Cancer

July 30, 2004

By Aaron Lorenzo

SGX Acquires First Clinical Drug: Troxatyl For Cancer

July 30, 2004

By Aaron Lorenzo

MannKind IPO Prices Within Range; Shares Close Higher

July 29, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...